<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Amikacin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00479</strong>&#160; (APRD00550)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Amikacin is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A. Similar to other aminoglycosides, amikacin disrupts bacterial protein synthesis by binding to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and tRNA acceptor sites leading  to the production of non-functional or toxic peptides. Other mechanisms not fully understood may confer the bactericidal effects of amikacin. Amikacin is also nephrotoxic and ototoxic.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00479/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00479/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00479.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00479.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00479.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00479.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00479.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00479">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Amikacin</td><td>German</td><td>INN</td></tr><tr><td>Amikacina</td><td>Spanish</td><td>INN</td></tr><tr><td>Amikacine</td><td>French</td><td>INN</td></tr><tr><td>Amikacinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Amikacin Sulfate</strong>
          <div class="cas">39831-55-5</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000351/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000351/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: FXKSEJFHKVNEFI-GCZBSULCSA-N</li>
              <li>Monoisotopic Mass: 781.220494971</li>
              <li>Average Mass: 781.759</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000351">DBSALT000351</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Amexel</td><td>Abbott</td></tr><tr><td>Amikin</td><td>Bristol-Myers Squibb</td></tr><tr><td>Amukin</td><td>Bristol-Myers Squibb</td></tr><tr><td>Biklin</td><td>Bristol-Myers Squibb</td></tr><tr><td>Erkacin</td><td>Brown &amp; Burk</td></tr><tr><td>Farcyclin</td><td>Faran Laboratories</td></tr><tr><td>Flexelite</td><td>Bros</td></tr><tr><td>Kamin</td><td>Bosch</td></tr><tr><td>Novamin</td><td>Bristol-Myers Squibb</td></tr><tr><td>Selaxa</td><td>Proel</td></tr><tr><td>Selemycin</td><td>Medochemie</td></tr><tr><td>Sikacin</td><td>Shiteh Organic</td></tr><tr><td>Tipkin</td><td>T P Drug</td></tr><tr><td>Tybikin</td><td>M &amp; H</td></tr><tr><td>Ukaject</td><td>Unimed Pharm</td></tr><tr><td>Unikin</td><td>Union</td></tr><tr><td>Uzix</td><td>Rafarm</td></tr><tr><td>Xylanal</td><td>Epsilon</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/aminoglycosides">Aminoglycosides</a></li></ul></td></tr><tr><th>CAS number</th><td>37517-28-5</td></tr><tr><th>Weight</th><td>Average: 585.6025<br>Monoisotopic: 585.285736487</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>43</sub>N<sub>5</sub>O<sub>13</sub></td></tr><tr><th>InChI Key</th><td>LKCWBDHBTVXHDL-RMDFUYIESA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Amino Sugars</td></tr><tr><th>Direct parent</th><td>Aminocyclitol Glycosides</td></tr><tr><th>Alternative parents</th><td>Dihexoses; Glycoamino Acids and Derivatives; O-glycosyl Compounds; Gamma Amino Acids and Derivatives; Aminocyclitols and Derivatives; Cyclohexanols; Oxanes; 1,2-Diols; Secondary Carboxylic Acid Amides; 1,2-Aminoalcohols; Enolates; Carboxylic Acids; Polyamines; Primary Alcohols; Acetals; Aldehydes; Monoalkylamines</td></tr><tr><th>Substituents</th><td>glyco amino acid; o-glycosyl compound; glycosyl compound; gamma amino acid or derivative; disaccharide; aminocyclitol derivative; cyclitol derivative; cyclohexanol; oxane; cyclic alcohol; carboxamide group; 1,2-diol; secondary carboxylic acid amide; secondary alcohol; polyol; 1,2-aminoalcohol; polyamine; acetal; carboxylic acid derivative; carboxylic acid; ether; enolate; primary alcohol; primary aliphatic amine; primary amine; organonitrogen compound; aldehyde; amine; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidially linked to a carbohydrate moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species. Amikacin may also be used to treat Mycobacterium avium and Mycobacterium tuberculosis infections.</td></tr><tr><th>Pharmacodynamics</th><td>Amikacin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.</td></tr><tr><th>Mechanism of action</th><td>Aminoglycosides like Amikacin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Amikacin inhibits protein synthesis by binding to the 30S ribosomal subunit to prevent the formation of an initiation complex with messenger RNA. Specifically Amikacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed after intramuscular administration. Rapid absorption occurs from the peritoneum and pleura. Poor oral and topical absorption. Poorly absorbed from bladder irrigations and intrathecal administration. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>24 L [normal adult subjects]</li>
</ul></td></tr><tr><th>Protein binding</th><td>0-11%</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Amikacin is excreted primarily by glomerular filtration.</td></tr><tr><th>Half life</th><td>2-3 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>100 mL/min</li>
</ul></td></tr><tr><th>Toxicity</th><td>Mild and reversible nephrotoxicity may be observed in 5 - 25% of patients. Amikacin accumulates in proximal renal tubular cells. Tubular cell regeneration occurs despite continued drug exposure. Toxicity usually occurs several days following initiation of therapy. 
May cause irreversible ototoxicity. Otoxocity appears to be correlated to cumulative lifetime exposure. Drug accumulation in the endolymph and perilymph of the inner ear causes irreversible damage to hair cells of the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing is lost first with progression leading to loss of low frequency hearing. Further toxicity may lead to retrograde degeneration of the 8th cranial (vestibulocochlear) nerve. Vestibular toxicity may cause vertigo, nausea, vomiting, dizziness and loss of balance. </td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Amikacin Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.9405</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7583</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5129</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7336</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8383</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8614</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.816</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5664</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9381</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9237</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9249</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9128</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9434</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6813
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9635
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.5512
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.7506 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9926
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6366
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abbott laboratories</li>
<li>Abbott laboratories hosp products div</li>
<li>Astrazeneca lp</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Hospira inc</li>
<li>Teva parenteral medicines inc</li>
<li>Apothecon inc div bristol myers squibb</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.meadjohnson.com">Mead Johnson and Co.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li>Sicor Pharmaceuticals</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00732">Atracurium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00887">Bumetanide</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB00456">Cefalotin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01326">Cefamandole</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01139">Cefapirin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01327">Cefazolin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01328">Cefonicid</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01329">Cefoperazone</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00923">Ceforanide</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00493">Cefotaxime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01330">Cefotetan</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01331">Cefoxitin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01333">Cefradine</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00438">Ceftazidime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01332">Ceftizoxime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01212">Ceftriaxone</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01112">Cefuroxime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00515">Cisplatin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01111">Colistimethate</a></td><td>Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. </td></tr><tr><td><a href="/drugs/DB01135">Doxacurium chloride</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00903">Ethacrynic acid</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB00695">Furosemide</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB01336">Metocurine</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01226">Mivacurium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01337">Pancuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01338">Pipecuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00728">Rocuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00202">Succinylcholine</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Amikacin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01041">Thalidomide</a></td><td>Thalidomide increases the renal toxicity of the aminoglycoside</td></tr><tr><td><a href="/drugs/DB01607">Ticarcillin</a></td><td>Ticarcillin may reduce the serum concentration of Amikacin. Ticarcillin may inactivate Amikacin in vitro and the two agents should not be administered simultaneously through the same IV line. </td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB01199">Tubocurarine</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01339">Vecuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>